GlassScriptPhysician profile
Christopher J Obrien
NPI 1780225623
$2,745.09
in general payments reported to CMS, 2019-2025
25 companies · $645 in 2025
The $645 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $292 · 2022: $330 · 2023: $758 · 2024: $720 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.99 |
| Education | $111.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $307.60 | 2021-2025 | |
| Vifor Pharma, INC. | $246.46 | 2021-2024 | Veltassa |
| Amgen INC. | $237.87 | 2022-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.60 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $181.74 | 2021-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $179.04 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $178.53 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $159.23 | 2024-2025 | |
| Glaxosmithkline, LLC. | $151.92 | 2023-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $131.64 | 2023-2024 | Rayaldee |
| Ardelyx, INC. | $127.32 | 2023-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $122.69 | 2021-2024 | Jynarque |
| Novo Nordisk INC | $89.26 | 2022-2025 | Ozempic |
| Travere Therapeutics, INC. | $81.40 | 2023-2025 | |
| Horizon Therapeutics Plc | $58.20 | 2021-2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $48.25 | 2024 | Velphoro |
| Abbott Laboratories | $44.13 | 2025 | Freestyle Libre 3, Architect |
| Ani Pharmaceuticals, INC. | $40.56 | 2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $33.17 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.56 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.97 | 2023 | Monoferric |
| Sanofi-Aventis U.S. LLC | $19.39 | 2021 | |
| Akebia Therapeutics INC | $17.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.